Thermedical Announces SERF VT Study Presented as Part of HRS 2020 Science Late-Breaking Clinical Trial Sessions

WALTHAM, Mass.–([1])–Thermedical®[2], a developer of thermal-ablation systems to treat ventricular tachycardia (VT), announced that results from a First-in-Human Early Feasibility Study (EFS) using the new Durablate® catheter to treat VT were presented in the late-breaking clinical trial sessions at the Heart Rhythm Society (HRS) meeting today.

Called the Saline Enhanced Radiofrequency (SERF) VT Ablation EFS[3], preliminary results were presented by the study’s Lead Investigator, Douglas L. Packer, M.D[4]., professor of medicine at the Mayo Clinic[5], on Heart Rhythm 365[6], the society’s digital education platform.

“Our data from the First-in-Human EFS suggest a highly feasible approach to treating patients with recurrent VT that is resistant to other treatments,” said Dr. Packer.

The SERF VT EFS is a groundbreaking, single-arm observational study designed to evaluate the safety and effectiveness of the Durablate[7] catheter to treat VT, a leading cause of sudden cardiac death worldwide. The target study population consists of patients who have failed all current forms of treatment including Implantable Cardioverter Defibrillators (ICDs), medical therapy and other forms of ablation therapy. The Durablate catheter uses a needle electrode to deliver heated, degassed saline and radiofrequency energy into the tissue to more effectively treat the tissue causing the VT than a standard, conventional ablation catheter.

Early feasibility results of 32 patients treated at six centers in the U.S. and Canada indicate that the SERF Durablate catheter is highly effective at eliminating clinical VT in patients with an acute procedural success rate of 100 percent and shows acceptable initial safety.

Five-month follow-up data demonstrate that more than half of the patients had no recurrent VT and more than 60 percent of the patients had their VT reduced by 90 percent or more. In contrast, for the six months prior to ablation, patients had a median of 40 ICD treatments (shock or antitachycardia pacing), which can significantly reduce quality of life. The Durablate catheter was used to deliver an average of 10 lesions per case and the average total procedure time was four hours and 42 minutes, which is significantly shorter than typical conventional RF procedures for patients of this nature.

“We are extremely encouraged by these early results as it puts us one step closer to advancing treatment that can reduce or eliminate VT episodes in patients,” said Michael Curley, Ph.D., FHRS[8], co-founder and chief executive officer of Thermedical. “Moreover, a successful and effective method to treat VT that is drastically shorter and more effective than current ablation procedures would improve quality of life considerably for people who develop, or who are at high risk of developing VT every year.

“We believe our SERF ablation therapy may serve as an adjunct to, or as a possible alternative to ICDs, and equally as important, it may be a low-cost alternative for treating VT, saving the U.S. healthcare system substantially in costs associated with current VT treatment,” added Dr. Curley.

The SERF VT EFS is underway in the U.S[9]. at Mayo Clinic[10], Loyola University Medical Center[11], and Vanderbilt University Medical Center[12], and in Canada[13] at Southlake Regional Health Centre[14], Montreal Heart Institute[15] and Quebec Heart and Lung Institute[16].

About Thermedical

Thermedical[17] is a privately held company founded by Massachusetts Institute of Technology (MIT) Hyperthermia Center alumni, Michael G. Curley, Ph.D. and Patrick S. Hamilton, Ph.D., based in Waltham, Mass. Under a Massachusetts Life Sciences Center Small Business Matching Grant (SBMG) Award, multiple NIH* Small Business Innovation Research (SBIR) Grants, and Series A venture funding, the company has developed thermal-ablation systems to treat VT and solid tumors. The Early Feasibility Study is the first human use of the Durablate Catheter Ablation System in the U.S. and Canada. For more information, visit www.thermedical.com[18].

About the Heart Rhythm Society

The Heart Rhythm Society is the international leader in science, education, and advocacy for cardiac arrhythmia professionals and patients and is the primary information resource on heart rhythm disorders. Its mission is to improve the care of patients by promoting research, education, and optimal health care policies and standards. Incorporated in 1979 and based in Washington, D.C., it has a membership of more than 7,000 heart rhythm professionals in more than 70 countries around the world. For more information, visit www.HRSonline.org[19].

* Research reported in this publication was supported by the National Heart, Lung, And Blood Institute of the National Institutes of Health under Award Number R44HL132746 and R44HL63535. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

References

  1. ^ (www.businesswire.com)
  2. ^ Thermedical® (cts.businesswire.com)
  3. ^ Saline Enhanced Radiofrequency (SERF) VT Ablation EFS (cts.businesswire.com)
  4. ^ Douglas L. Packer, M.D (cts.businesswire.com)
  5. ^ Mayo Clinic (cts.businesswire.com)
  6. ^ Heart Rhythm 365 (cts.businesswire.com)
  7. ^ Durablate (cts.businesswire.com)
  8. ^ Michael Curley, Ph.D., FHRS (cts.businesswire.com)
  9. ^ U.S (cts.businesswire.com)
  10. ^ Mayo Clinic (cts.businesswire.com)
  11. ^ Loyola University Medical Center (cts.businesswire.com)
  12. ^ Vanderbilt University Medical Center (cts.businesswire.com)
  13. ^ Canada (cts.businesswire.com)
  14. ^ Southlake Regional Health Centre (cts.businesswire.com)
  15. ^ Montreal Heart Institute (cts.businesswire.com)
  16. ^ Quebec Heart and Lung Institute (cts.businesswire.com)
  17. ^ Thermedical (cts.businesswire.com)
  18. ^ www.thermedical.com (cts.businesswire.com)
  19. ^ www.HRSonline.org (cts.businesswire.com)

Source URL: Read More
The public content above was dynamically discovered – by graded relevancy to this site’s keyword domain name. Such discovery was by systematic attempts to filter for “Creative Commons“ re-use licensing and/or by Press Release distributions. “Source URL” states the content’s owner and/or publisher. When possible, this site references the content above to generate its value-add, the dynamic sentimental analysis below, which allows us to research global sentiments across a multitude of topics related to this site’s specific keyword domain name. Additionally, when possible, this site references the content above to provide on-demand (multilingual) translations and/or to power its “Read Article to Me” feature, which reads the content aloud to visitors. Where applicable, this site also auto-generates a “References” section, which appends the content above by listing all mentioned links. Views expressed in the content above are solely those of the author(s). We do not endorse, offer to sell, promote, recommend, or, otherwise, make any statement about the content above. We reference the content above for your “reading” entertainment purposes only. Review “DMCA & Terms”, at the bottom of this site, for terms of your access and use as well as for applicable DMCA take-down request.

Acquire this Domain
You can acquire this site’s domain name! We have nurtured its online marketing value by systematically curating this site by the domain’s relevant keywords. Explore our content network – you can advertise on each or rent vs. buy the domain. Buy@TLDtraders.com | Skype: TLDtraders | +1 (475) BUY-NAME (289 – 6263). Thousands search by this site’s exact keyword domain name! Most are sent here because search engines often love the keyword. This domain can be your 24/7 lead generator! If you own it, you could capture a large amount of online traffic for your niche. Stop wasting money on ads. Instead, buy this domain to gain a long-term marketing asset. If you can’t afford to buy then you can rent the domain.

About Us
We are Internet Investors, Developers, and Franchisers – operating a content network of several thousand sites while federating 100+ eCommerce and SaaS startups. With our proprietary “inverted incubation” model, we leverage a portfolio of $100M in valued domains to impact online trends, traffic, and transactions. We use robotic process automation, machine learning, and other proprietary approaches to power our content network. Contact us to learn how we can help you with your online marketing and/or site maintenance.

Share